ESSA Pharma/EPIX

$8.18

1.74%
-
1D1W1MYTD1YMAX

About ESSA Pharma

ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The Company is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The Company is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.

Ticker

EPIX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

David Parkinson

Employees

50

Headquarters

Vancouver, Canada

ESSA Pharma Metrics

BasicAdvanced
$348.6M
Market cap
-
P/E ratio
-$0.59
EPS
1.59
Beta
-
Dividend rate

What the Analysts think about ESSA Pharma

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 6 analysts.
140.46% upside
High $29.00
Low $15.00
$8.18
Current price
$19.67
Average price target

ESSA Pharma Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-
Net income
$-5.9M
9.26%
Profit margin
0%
-

ESSA Pharma Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 18.84%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.16
-$0.17
-$0.12
-$0.14
-
Expected
-$0.21
-$0.20
-$0.21
-$0.17
-$0.19
Surprise
-21.95%
-12.82%
-42.86%
-18.84%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell ESSA Pharma stock

Buy or sell ESSA Pharma stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing